Home > Healthcare > Biotechnology > Biotechnology R&D > Non-animal Alternative Testing Market
Non-Animal Alternative Testing Market size was valued at USD 1.7 billion in 2022 and will progress tremendously to reach over USD 4.5 billion by 2032 at 10.3% CAGR. The high market growth is owing to the rising emphasis on animal welfare as part of global sustainable development goals.
While animal models are critical to biomedical research for drug and treatment developments, research agencies are encouraging the adoption of complementary approaches or alternatives to animal testing. Additionally, adoption of the 3R principles (replacement, reduction, and refinement) by both regulatory bodies and end-use industries, specifically in the field of pharmaceuticals is expected to drive the market for non-animal alternative testing during projection period.
Non-animal alternative testing are methods for replacing animals used in experiments such as clinical studies for drug development with algorithms and computational programs in order to avoid animal cruelty and maintain ethical practices while achieving maximum accuracy in experiments such as finding potential drug molecules.